Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Not yet recruiting 2Recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3

Conditions

Small Cell Lung Carcinoma 9Carcinoma, Non-Small-Cell Lung 7Sarcoma 5Breast Neoplasms 4Triple Negative Breast Neoplasms 3Thyroid Neoplasms 3Nasopharyngeal Carcinoma 3Pancreatic Neoplasms 2Neoplasm Metastasis 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Whole-Brain Radiotherapy 1Stomach Neoplasms 1Solid Tumors 1Small Cell Lung Cancer Extensive Stage 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Recurrence 1Proteinuria 1Progression Free Survival(PFS) 1Platinum-resistant Ovarian Cancer (PROC) 1Ovarian Neoplasms 1Lung Neoplasms 1Leiomyosarcoma 1HER2-Negative Breast Cancer 1Gallbladder Neoplasms 1Fallopian Tube Neoplasms 1Extensive Stage Lung Small Cell Cancer 1Esophageal Neoplasms 1

Interventions

Cisplatin 32Gemcitabine 21Radiotherapy, Intensity-Modulated 16toripalimab 14Capecitabine 11Magnetic Resonance Spectroscopy 10Specimen Handling 9Radiotherapy 7Drug Therapy 7pembrolizumab 6Platinum 6Nivolumab 6Immune Checkpoint Inhibitors 61,2-diaminocyclohexaneplatinum II citrate 6Docetaxel 5tislelizumab 4spartalizumab 4camrelizumab 4sintilimab 3anlotinib 3Immunoglobulin G 3Disulfides 3Carboplatin 3nimotuzumab 2fludarabine 2atezolizumab 2Taxes 2Radiation 2Phantoms, Imaging 2Ipilimumab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Nasopharyngeal Carcinoma × anlotinib × 1 year × Clear all
NCT07581821 2026-05-12

Sintilimab Combined With Anlotinib and Taxane-Based Chemotherap for Recurrent/Metastatic Nasopharyngeal Carcinoma

Sun Yat-sen University

Phase 2 Recruiting
33 enrolled
Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT07540390 2026-04-22

GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC.

Sun Yat-sen University

Phase 3 Not yet recruiting
442 enrolled
Head & Neck

Nasopharyngeal Carcinoma

NCT07320963 2026-03-20

Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.

Sun Yat-sen University

Phase 1/2 Not yet recruiting
52 enrolled
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡